Avita Medical stock gained 4.17 percent near its yearly high

Published on 10/06/2026 at 12:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Avita Medical raised 2026 revenue guidance to USD 86 million-USD 89 million on September 16, 2026. Q2 revenue reached USD 21.70 million.

RCEL, AU000000AVH4, Illustration mit AI erstellt.

Avita Medical stock (ISIN AU000000AVH4) gained 4.17 percent to USD 13.25 at 4:00 p.m. ET on October 5, 2026, putting the Nasdaq-listed medical-device company within USD 0.23 of its 52-week high of USD 13.48. The move followed a period of improving operating figures, while management's updated revenue outlook remains the central company milestone.

Revenue guidance moves higher

According to Investing.com on September 16, 2026, AVITA raised its 2026 revenue guidance to USD 86 million-USD 89 million from USD 80 million-USD 85 million. The midpoint rose from USD 82.5 million to USD 87.5 million, an increase of 6.1 percent.

The same company presentation indicated second-quarter cash burn of USD 3.2 million and a target of cash-flow breakeven in the fourth quarter of 2026. That makes execution against the raised revenue range more important than the single-session share move.

Q2 revenue beats consensus

MarketBeat reported that AVITA's second-quarter 2026 revenue was USD 21.70 million, above the USD 20.25 million consensus estimate. The quarterly adjusted loss was USD 0.25 per share versus the expected USD 0.29 loss, a USD 0.04 improvement against consensus.

Finance figures for Q2 2026 show revenue of USD 21.702 million, gross profit of USD 17.767 million and a gross margin of 82 percent. Revenue increased from USD 19.251 million in Q1 2026 to USD 21.702 million in Q2, a sequential gain of 12.7 percent.

Analysts remain constructive

Paasa lists a Buy consensus based on 7 Buy ratings, 1 Hold rating and 0 Sell ratings, with a median 12-month price target of USD 11.50. The published target range runs from USD 11.00 to USD 12.00, below the October 5 share price.

The counter-factor is cash generation. Operating cash flow was negative USD 7.663 million in Q2 2026, although that was an improvement from negative USD 10.292 million in Q1. Management's fourth-quarter breakeven target therefore remains the measurable test for the updated growth narrative.

Avita Medical stock nears yearly high

Avita Medical stock was last at USD 13.25 on Nasdaq on October 5, 2026, at 4:00 p.m. ET. The USD 329.2 million market capitalization and 418,484-share volume place the latest move in the context of a stock trading USD 0.23 below its 52-week high.